Radiosensitising nanoparticles as novel cancer therapeutics - Pipe dream or realistic prospect?

Clinical Oncology

Volumn 25, Issue 10, 2013, Pages 593-603

  Coulter, J A ^a   Hyland, W B ^a,b   Nicol, J ^a   Currell, F J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Cancer; Nanoparticles; Nanotechnology; Radiation dose enhancement

Indexed keywords

AUROLASE; AUROSHELLS; CYT 6091; GADOLINIUM; GADOLINIUM TEXAPHYRIN; GOLD NANOPARTICLE; RADIOSENSITIZING AGENT; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SILVER NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER THERAPY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MECHANISM; HUMAN; HYPERTENSION; HYPOTENSION; LIVER TOXICITY; MALAISE; NANOTECHNOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RADIOSENSITIZATION;

CANCER; NANOPARTICLES; NANOTECHNOLOGY; RADIATION DOSE ENHANCEMENT;

ANIMALS; HUMANS; NANOPARTICLES; NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 84883273379     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.06.011     Document Type: Article

References (66)

1. Lee S.J., Atala A. Scaffold technologies for controlling cell behavior in tissue engineering. Biomed Mater 2013, 8(1):1-2. 010201.
2. Siccardi M., Martin P., McDonald T.O., et al. Research spotlight: nanomedicines for HIV therapy. Ther Deliv 2013, 4(2):153-156.
3. Ali H.M., Urbinati G., Raouane M., Massaad-Massade L. Significance and applications of nanoparticles in siRNA delivery for cancer therapy. Expert Rev Clin Pharmacol 2012, 5(4):403-412.
4. Kumar P., Gulbake A., Jain S.K. Liposomes a vesicular nanocarrier: potential advancements in cancer chemotherapy. Crit Rev Ther Drug Carrier Syst 2012, 29(5):355-419.
5. Jain S., Coulter J.A., Hounsell A.R., et al. Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies. Int J Radiat Oncol Biol Phys 2011, 79(2):531-539.
6. Shukla R., Bansal V., Chaudhary M., Basu A., Bhonde R.R., Sastry M. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir 2005, 21(23):10644-10654.
7. Espinoza-Castaneda M., de la Escosura-Muniz A., Gonzalez-Ortiz G., Martin-Orue S.M., Perez J.F., Merkoci A. Casein modified gold nanoparticles for future theranostic applications. Biosens Bioelectron 2013, 40(1):271-276.
8. Miladi I., Le Duc G., Kryza D., et al. Biodistribution of ultra small gadolinium-based nanoparticles as theranostic agent: application to brain tumors. JBiomater Appl 2012 Jul 24, [Epub ahead of print].
9. Meesungnoen J., Jay-Gerin J.P., Filali-Mouhim A., Mankhetkorn S. Low-energy electron penetration range in liquid water. Radiat Res 2002, 158(5):657-660.
10. McMahon S.J., Hyland W.B., Muir M.F., et al. Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles. Sci Rep 2011, 1:18.
11. McMahon S.J., Hyland W.B., Muir M.F., et al. Nanodosimetric effects of gold nanoparticles in megavoltage radiation therapy. Radiother Oncol 2011, 100(3):412-416.
12. Azizzadeh B., Yip H.T., Blackwell K.E., et al. Nitric oxide improves cisplatin cytotoxicity in head and neck squamous cell carcinoma. Laryngoscope 2001, 111(11 Pt 1):1896-1900.
13. Butterworth K.T., McMahon S.J., Currell F.J., Prise K.M. Physical basis and biological mechanisms of gold nanoparticle radiosensitization. Nanoscale 2012, 4(16):4830-4838.
14. Zhao D., Sun X., Tong J., et al. Anovel multifunctional nanocomposite C225-conjugated Fe3O4/ag enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy. Acta Biochim Biophys Sin (Shanghai) 2012, 44(8):678-684.
15. Pan J., Kong L., Lin S., Chen G., Chen Q., Lu J.J. The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma. Laryngoscope 2008, 118(11):1970-1975.
16. Ruan L., Li X.H., Wan X.X., et al. Analysis of EGFR signaling pathway in nasopharyngeal carcinoma cells by quantitative phosphoproteomics. Proteome Sci 2011, 9(35).
17. Kang Y., Park M.A., Heo S.W., et al. The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells. Biochim Biophys Acta 2012, 1830(3):2638-2648.
18. Skvortsova I., Skvortsov S., Stasyk T., et al. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 2008, 8(21):4521-4533.
19. Xu R., Ma J., Sun X., et al. Ag nanoparticles sensitize IR-induced killing of cancer cells. Cell Res 2009, 19(8):1031-1034.
20. AshaRani P.V., Low Kah Mun G., Hande M.P., Valiyaveettil S. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano 2009, 3(2):279-290.
21. Lim H.K., Asharani P.V., Hande M.P. Enhanced genotoxicity of silver nanoparticles in DNA repair deficient mammalian cells. Front Genet 2012, 3:104.
22. Bentle M.S., Reinicke K.E., Dong Y., Bey E.A., Boothman D.A. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone. Cancer Res 2007, 67(14):6936-6945.
23. Groselj B., Sharma N.L., Hamdy F.C., Kerr M., Kiltie A.E. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer 2013, 108(4):748-754. 10.1038/bjc.2013.21.
24. Le Duc G., Miladi I., Alric C., et al. Toward an image-guided microbeam radiation therapy using gadolinium-based nanoparticles. ACS Nano 2011, 5(12):9566-9574.
25. Maeda H., Sawa T., Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. JControl Release 2001, 74(1-3):47-61.
26. Iyer A.K., Khaled G., Fang J., Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006, 11(17-18):812-818.
27. Jo J., Schiff D., Purow B. Angiogenic inhibition in high-grade gliomas: past, present and future. Expert Rev Neurother 2012, 12(6):733-747.
28. Young S.W., Qing F., Harriman A., et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci USA 1996, 93(13):6610-6615.
29. Khuntia D., Mehta M. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther 2004, 4(6):981-989.
30. Chang J.E., Khuntia D., Robins H.I., Mehta M.P. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 2007, 5(11). 894,902,907-894,902,915.
31. Hashemy S.I., Ungerstedt J.S., Zahedi Avval F., Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. JBiol Chem 2006, 281(16):10691-10697.
32. Edelman M.J., Otterson G., Leach J., et al. Multicenter phase II trial of motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. JThorac Oncol 2011, 6(4):786-789.
33. Carde P., Timmerman R., Mehta M.P., et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. JClin Oncol 2001, 19(7):2074-2083.
34. Bradley K.A., Pollack I.F., Reid J.M., et al. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol 2008, 10(5):752-758.
35. Aaseth J., Haugen M., Forre O. Rheumatoid arthritis and metal compounds -perspectives on the role of oxygen radical detoxification. Analyst 1998, 123(1):3-6.
36. Regulla D.F., Hieber L.B., Seidenbusch M. Physical and biological interface dose effects in tissue due to X-ray-induced release of secondary radiation from metallic gold surfaces. Radiat Res 1998, 150(1):92-100.
37. Herold D.M., Das I.J., Stobbe C.C., Iyer R.V., Chapman J.D. Gold microspheres: a selective technique for producing biologically effective dose enhancement. Int J Radiat Biol 2000, 76(10):1357-1364.
38. Hainfeld J.F., Slatkin D.N., Smilowitz H.M. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 2004, 49(18):N309-N315.
39. Coulter J.A., Jain S., Butterworth K.T., et al. Cell type-dependent uptake, localization, and cytotoxicity of 1.9nm gold nanoparticles. Int J Nanomed 2012, 7:2673-2685.
40. Roeske J.C., Nunez L., Hoggarth M., Labay E., Weichselbaum R.R. Characterization of the theorectical radiation dose enhancement from nanoparticles. Technol Cancer Res Treat 2007, 6(5):395-401.
41. Kong T., Zeng J., Wang X., et al. Enhancement of radiation cytotoxicity in breast-cancer cells by localized attachment of gold nanoparticles. Small 2008, 4(9):1537-1543.
42. Rahman W.N., Bishara N., Ackerly T., et al. Enhancement of radiation effects by gold nanoparticles for superficial radiation therapy. Nanomedicine 2009, 5(2):136-142.
43. Chithrani D.B., Jelveh S., Jalali F., et al. Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res 2010, 173(6):719-728.
44. Liu C.J., Wang C.H., Chen S.T., et al. Enhancement of cell radiation sensitivity by pegylated gold nanoparticles. Phys Med Biol 2010, 55(4):931-945.
45. Geng F., Song K., Xing J.Z., et al. Thio-glucose bound gold nanoparticles enhance radio-cytotoxic targeting of ovarian cancer. Nanotechnology 2011, 22(28):285101.
46. Hainfeld J.F., Dilmanian F.A., Zhong Z., Slatkin D.N., Kalef-Ezra J.A., Smilowitz H.M. Gold nanoparticles enhance the radiation therapy of a murine squamous cell carcinoma. Phys Med Biol 2010, 55(11):3045-3059.
47. Hainfeld J.F., Smilowitz H.M., O'Connor M.J., Dilmanian F.A., Slatkin D.N. Gold nanoparticle imaging and radiotherapy of brain tumors in mice. Nanomedicine (Lond) 2012, [Epub ahead of print].
48. van Vlerken L.E., Vyas T.K., Amiji M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res 2007, 24(8):1405-1414.
49. Kumar D., Meenan B.J., Dixon D. Glutathione-mediated release of bodipy(R) from PEG cofunctionalized gold nanoparticles. Int J Nanomed 2012, 7:4007-4022.
50. Chattopadhyay N., Cai Z., Kwon Y.L., Lechtman E., Pignol J.P., Reilly R.M. Molecularly targeted gold nanoparticles enhance the radiation response of breast cancer cells and tumor xenografts to X-radiation. Breast Cancer Res Treat 2013, 137(1):81-91.
51. 4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides. Bioconjug Chem 2011, 22(4):766-776.
52. McLaughlin M.F., Woodward J., Boll R.A., et al. Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy. PLoS One 2013, 8(1). e54531.
53. Kimura K., Taguchi T., Urushizaki I., et al. Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1987, 20(3):223-229.
54. Taguchi T. Phase I study of recombinant human tumor necrosis factor (rHu-TNF: PT-050). Cancer Detect Prev 1988, 12(1-6):561-572.
55. Heim M.E., Siegmund R., Illiger H.J., et al. Tumor necrosis factor in advanced colorectal cancer: a phase II study. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie 1990, 13(6):444-447.
56. Whitehead R.P., Fleming T., Macdonald J.S., et al. Aphase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group Study. JBiol Response Mod 1990, 9(6):588-591.
57. Paciotti G.F., Myer L., Weinreich D., et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 2004, 11(3):169-183.
58. Powell A.C., Paciotti G.F., Libutti S.K. Colloidal gold: a novel nanoparticle for targeted cancer therapeutics. Methods Mol Biol 2010, 624:375-384.
59. Libutti S.K., Paciotti G.F., Byrnes A.A., et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 2010, 16(24):6139-6149.
60. Gad S.C., Sharp K.L., Montgomery C., Payne J.D., Goodrich G.P. Evaluation of the toxicity of intravenous delivery of auroshell particles (gold-silica nanoshells). Int J Toxicol 2012, 31(6):584-594.
61. El-Sayed I.H. Nanotechnology in head and neck cancer: the race is on. Curr Oncol Rep 2010, 12(2):121-128.
62. Butterworth K.T., Coulter J.A., Jain S., et al. Evaluation of cytotoxicity and radiation enhancement using 1.9 nm gold particles: potential application for cancer therapy. Nanotechnology 2010, 21(29):295101.
63. Roa W., Zhang X., Guo L., et al. Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle. Nanotechnology 2009, 20(37):375101.
64. Chang M.Y., Shiau A.L., Chen Y.H., et al. Increased apoptotic potential and dose-enhancing effect of gold nanoparticles in combination with single-dose clinical electron beams on tumor-bearing mice. Cancer Sci 2008, 99:1479-1484.
65. Chien C.C., Wang C.H., Hua T.E., et al. Synchrotron X-ray synthesized gold nanoparticles for tumour therapy. Synchrotron Radiation Instrumentation. AIP Conference Proceedings 2007, 879:1908-1911.
66. Zhang X., Xing J.Z., Chen J., et al. Enhanced radiation sensitivity in prostate cancer by gold-nanoparticles. Clin Invest Med 2008, 31(3):E160-E167.